Pharmacogenomics: When Your Genes Determine Which Quit Method Works for You
Genetic variation affects response to every smoking cessation medication. CYP2A6 genotype predicts NRT response. CHRNA5 genotype predicts varenicline response. Personalized cessation—matching the treatment to the patient's genetics—is the future of quitting.
Slow nicotine metabolizers (CYP2A6 variants) respond well to NRT—the nicotine stays in their system longer, reducing craving. Normal metabolizers respond better to varenicline—which bypasses the metabolic pathway. **The evidence for genetically-guided smoking cessation is strong enough that clinical implementation is beginning. The smoker who has tried and failed to quit with one medication may succeed with another—and genetics can help predict which one. Personalized cessation is the future. The present is still one-size-fits-all.**
